All In Biotech

Drug Trial Radar · NCT03008070

Phase 2b Study in NASH to Assess IVA337

A Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-range, Proof-of-concept, 24-week Treatment Study of IVA337 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)

Last checked: Nov 19, 2026Latest source record: Jul 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 247 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

247

Actual

Start

Feb 7, 2017

Primary completion

Feb 20, 2020

Study completion Mar 16, 2020

Sponsor

Lead sponsor
Inventiva PharmaIndustry
Sponsor type
Industry
First posted
Jan 2, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Non-alcoholic steatohepatitis, abbreviated as NASH, is a chronic liver disease that may progress to cirrhosis. The disease is mostly associated with obesity and type 2 diabetes mellitus, or insulin resistance and is very common. However, Treatment of NASH is a significant unmet clinical need. IVA337 (lanifibranor) is a next generation pan-PPAR (peroxisome proliferator-activated receptors) agonist addressing the pathophysiology of NASH : metabolic, inflammatory and fibrotic. The purpose of this research is to evaluate the efficacy and the safety of two doses of IVA337 (800mg, 1200 mg) per day for 24 weeks versus placebo in adult NASH patients with liver steatosis and moderate to severe necroinflammation without cirrhosis.

Conditions

  • Non-Alcoholic Steatohepatitis (NASH)

Interventions

  • IVA337Drug

    1200mg

  • IVA337Drug

    800mg

  • PlaceboDrug

    Placebo to match

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SAF Activity Score (SAF-A) Decrease of at Least 2 Points With no Worsening of the CRN Fibrosis Score (CRN-F)Time frame: 24 weeks

Locations

85 sites in 16 countries. Site status is shown where the registry gives one.

  • North Alabama GI Research Center

    Madison, Alabama

  • ACTRI

    La Jolla, California

  • National Research Institute

    Los Angeles, California

  • Palmetto Research, LLC

    Hialeah, Florida

  • Florida Digestive Health Specialists, LLP

    Lakewood Rch, Florida

  • Northeast GI Research Division

    Concord, Massachusetts

  • Duke University Medical Center

    Durham, North Carolina

  • Carolina's Center for Liver Disease/CHG

    Huntersville, North Carolina

  • Jefferson University hospital

    Philadelphia, Pennsylvania

  • Digestive Health Research, LLC

    Hermitage, Tennessee

  • The Texas Liver Institute

    San Antonio, Texas

  • Digestive Health Research, LLC

    San Antonio, Texas

  • University of Virginia Health System

    Charlottesville, Virginia

  • Virginia Commonwealth University

    Richmond, Virginia

  • Flinders Medical Centre Department of Hepatology

    Bedford Park, Australia

  • Monash Medical Centre

    Clayton, Australia

  • Lyell McEwin Hospital & The University of Adelaide

    Elizabeth Vale, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Australia

  • Fiona Stanley Hospital

    Murdoch, Australia

  • Medical University Vienna

    Vienna, Austria

  • Hopital Erasme

    Brussels, Belgium

  • Clinique Universitaire Saint-luc

    Brussels, Belgium

  • Antwerp University Hospital

    Edegem, Belgium

  • Ziekenhuis Oost Limburg

    Genk, Belgium

  • UZ Gent

    Ghent, Belgium

  • "DCC Alexandrovska", EOOD

    Sofia, Bulgaria

  • Acibadem City Clinic Tokuda Hospital

    Sofia, Bulgaria

  • Acibadem City Clinic University Hospital EOOD

    Sofia, Bulgaria

  • MHAT "Sveta Anna" Sofia

    Sofia, Bulgaria

  • Military Medical Academy - MHAT

    Sofia, Bulgaria

  • UMHAT "Sv. Ivan Rilski"

    Sofia, Bulgaria

  • UMHAT "Tsaritsa Yoanna-ISUL"

    Sofia, Bulgaria

  • University of Calgary

    Calgary, Canada

  • The Bailey Health Clinic

    Edmonton, Canada

  • CISSS de la Montérégie Centre

    Greenfield Park, Canada

  • University of Western Ontario, London Health Sciences Centre

    London, Canada

  • McGill University Health Centre (MUHC)

    Montreal, Canada

  • Medpharmgene, Inc

    Montreal, Canada

  • LAIR Centre

    Vancouver, Canada

  • Researchsite S.R.O.

    Pilsen, Czechia

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.